Luxembourg Institute of Health
Strassen, Luxembourg
NCT Number: NCT05546918
The UpcomingVoice project aims to co-design a digital health solution based on vocal biomarkers for screening and self-monitoring of frequently reported COVID-19-related symptoms with its end-users: 1) people with persisting COVID-19 related symptoms, with or without a Long COVID diagnosis and 2) healthcare professionals involved in the care of Long COVID patients.
To achieve this objective the UpcomingVoice study will determine:
* The needs, expectancies, acceptability, fears, barriers and leverages of the end-users regarding the use of voice to self-monitor or screen for Long COVID symptoms * The specifications that such a mobile application should meet in order to be considered acceptable and effective by its intended users in terms of technological aspects (type of device, type of voice recordings…), frequency of utilisation, design etc.
The project consists in 2 separate parts : one anonymous online survey and one qualitative part based on semi-structured interviews and focus groups.
The results of this study will be the specifications of a voice-based digital health solution.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Strassen, Luxembourg
The COVID-19 pandemic accelerated the use of remote patient monitoring in clinical practice or research for safety and emergency reasons, justifying the need for innovative digital health solutions to monitor key parameters or symptoms related to COVID-19 or Long COVID. A panel of experts from the National Institute for Health and Care Excellence (NICE) recommended the development of telemonitoring and encouraged self-management of acute and Long COVID symptoms in a tailored and accessible way for each patient.
Voice is an interesting approach to use for telemonitoring as it is easy-to-collect, quick, energy efficient, and inducing less burden for patients. To bring vocal biomarkers of different symptoms into clinical and real-life practice, they have to be implemented in a digital health solution, for example a smartphone application.
It is crucial to involve the end-users in the development of such a digital health solution and in this project involve them during the entire project course.
The study protocol, the participant's documents, and the questionnaires have been reviewed by both Long COVID patients and HCPs prior to submission.
The co-design process will consist in 3 steps, each involving both patients and HCPs:
The project is based on a mixed methods study and will integrate both qualitative and quantitative methods. Participants will be invited to participate in:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The 2 groups of participants will be invited to:
Time frame: At baseline
Specific questions will be asked in the online survey and during an individual online interview to identify the needs, expectancies, acceptability, fears, barriers and leverages regarding the use of voice as a monitoring tool
Time frame: At baseline
Specific questions will be asked in the online survey, during an individual online interview and during focus groups regarding the main dimensions of a digital health solution (Engagement, functionality, aesthetics, information and general items ("Would you recommend", "Would you be interested in", etc..)
Luxembourg Institute of Health
Other Gov
Users' Expectations and Co-design of a Digital Health Solution to Monitor Persisting Symptoms Related to COVID-19 Using Voice: a Mixed-methods Study
Acronym: UpcomingVoice
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05745805
Acute COVID-19, COVID-19
Xi'an, Shaanxi, China
View Trial DetailsNCT07722000
COVID-19, Chronic Disease
Banī Suwayf, Beni Suweif Governorate, Egypt
View Trial DetailsNCT05876377
COVID-19, Chronic Disease
New York, United States
View Trial DetailsNCT05920616
COVID Long-Haul, COVID-19
Baltimore, Maryland, United States
View Trial Details